BACKGROUND: Aging in men is characterized by a progressive decline in levels of anabolic hormones, such as testosterone, insulinlike growth factor 1 (IGF-1), and dehydroepiandrosterone sulfate (DHEA-S). We hypothesized that in older men a parallel age-associated decline in bioavailable testosterone, IGF-1, and DHEA-S secretion is associated with higher mortality independent of potential confounders. METHODS: Testosterone, IGF-1, DHEA-S, and demographic features were evaluated in a representative sample of 410 men 65 years and older enrolled in the Aging in the Chianti Area (InCHIANTI) study. A total of 126 men died during the 6-year follow-up. Thresholds for lowest-quartile definitions were 70 ng/dL (to convert to nanomoles per liter, multiply by 0.0347) for bioavailable testosterone, 63.9 ng/mL (to convert to nanomoles per liter, multiply by 0.131) for total IGF-1, and 50 microg/dL (to convert to micromoles per liter, multiply by 0.027) for DHEA-S. Men were divided into 4 groups: no hormone in the lowest quartile (reference) and 1, 2, and 3 hormones in the lowest quartiles. Kaplan-Meier survival and Cox proportional hazards models adjusted for confounders were used in the analysis. RESULTS: Compared with men with levels of all 3 hormones above the lowest quartiles, having 1, 2, and 3 dysregulated hormones was associated with hazard ratios for mortality of 1.47 (95% confidence interval [CI], 0.88-2.44), 1.85 (95% CI, 1.04-3.30), and 2.29 (95% CI, 1.12-4.68), respectively (test for trend, P <.001). In the fully adjusted analysis, only men with 3 anabolic hormone deficiencies had a significant increase in mortality (hazard ratio, 2.44; 95% CI, 1.09-5.46 (test for trend, P <.001). CONCLUSIONS: Age-associated decline in anabolic hormone levels is a strong independent predictor of mortality in older men. Having multiple hormonal deficiencies rather than a deficiency in a single anabolic hormone is a robust biomarker of health status in older persons.
BACKGROUND: Aging in men is characterized by a progressive decline in levels of anabolic hormones, such as testosterone, insulinlike growth factor 1 (IGF-1), and dehydroepiandrosterone sulfate (DHEA-S). We hypothesized that in older men a parallel age-associated decline in bioavailable testosterone, IGF-1, and DHEA-S secretion is associated with higher mortality independent of potential confounders. METHODS:Testosterone, IGF-1, DHEA-S, and demographic features were evaluated in a representative sample of 410 men 65 years and older enrolled in the Aging in the Chianti Area (InCHIANTI) study. A total of 126 men died during the 6-year follow-up. Thresholds for lowest-quartile definitions were 70 ng/dL (to convert to nanomoles per liter, multiply by 0.0347) for bioavailable testosterone, 63.9 ng/mL (to convert to nanomoles per liter, multiply by 0.131) for total IGF-1, and 50 microg/dL (to convert to micromoles per liter, multiply by 0.027) for DHEA-S. Men were divided into 4 groups: no hormone in the lowest quartile (reference) and 1, 2, and 3 hormones in the lowest quartiles. Kaplan-Meier survival and Cox proportional hazards models adjusted for confounders were used in the analysis. RESULTS: Compared with men with levels of all 3 hormones above the lowest quartiles, having 1, 2, and 3 dysregulated hormones was associated with hazard ratios for mortality of 1.47 (95% confidence interval [CI], 0.88-2.44), 1.85 (95% CI, 1.04-3.30), and 2.29 (95% CI, 1.12-4.68), respectively (test for trend, P <.001). In the fully adjusted analysis, only men with 3 anabolic hormone deficiencies had a significant increase in mortality (hazard ratio, 2.44; 95% CI, 1.09-5.46 (test for trend, P <.001). CONCLUSIONS: Age-associated decline in anabolic hormone levels is a strong independent predictor of mortality in older men. Having multiple hormonal deficiencies rather than a deficiency in a single anabolic hormone is a robust biomarker of health status in older persons.
Authors: S D Anker; A L Clark; M Kemp; C Salsbury; M M Teixeira; P G Hellewell; A J Coats Journal: J Am Coll Cardiol Date: 1997-10 Impact factor: 24.094
Authors: G P Ceda; E Dall'Aglio; A Magnacavallo; N Vargas; V Fontana; M Maggio; G Valenti; P D Lee; R L Hintz; A R Hoffman Journal: J Clin Endocrinol Metab Date: 1998-02 Impact factor: 5.958
Authors: J E Morley; F E Kaiser; H M Perry; P Patrick; P M Morley; P M Stauber; B Vellas; R N Baumgartner; P J Garry Journal: Metabolism Date: 1997-04 Impact factor: 8.694
Authors: G P Ceda; E Dall'Aglio; M Maggio; F Lauretani; S Bandinelli; C Falzoi; W Grimaldi; G Ceresini; F Corradi; L Ferrucci; G Valenti; A R Hoffman Journal: J Endocrinol Invest Date: 2005 Impact factor: 4.256
Authors: Steve Hoffmann; Karol Szafranski; Philip Dammann; Arne Sahm; Matthias Platzer; Philipp Koch; Yoshiyuki Henning; Martin Bens; Marco Groth; Hynek Burda; Sabine Begall; Saskia Ting; Moritz Goetz; Paul Van Daele; Magdalena Staniszewska; Jasmin Mona Klose; Pedro Fragoso Costa Journal: Elife Date: 2021-03-16 Impact factor: 8.140
Authors: M Maggio; G P Ceda; F Lauretani; C Cattabiani; E Avantaggiato; S Morganti; F Ablondi; S Bandinelli; L J Dominguez; M Barbagallo; G Paolisso; R D Semba; L Ferrucci Journal: Int J Androl Date: 2011-06-15
Authors: David de Gonzalo-Calvo; Benjamín Fernández-García; Beatriz de Luxán-Delgado; Susana Rodríguez-González; Marina García-Macia; Francisco Manuel Suárez; Juan José Solano; María Josefa Rodríguez-Colunga; Ana Coto-Montes Journal: Age (Dordr) Date: 2011-06-04
Authors: Andy Menke; Eliseo Guallar; Sabine Rohrmann; William G Nelson; Nader Rifai; Norma Kanarek; Manning Feinleib; Erin D Michos; Adrian Dobs; Elizabeth A Platz Journal: Am J Epidemiol Date: 2010-01-18 Impact factor: 4.897